Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent

NCT01956734 is registered in ClinicalTrials.gov with Clinica Universidad de Navarra, Universidad de Navarra as lead sponsor.

NCT NCT01956734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01956734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent
Lead sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2013
Completion date
March 31, 2017
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, recurrent tumor